Diplomat Pharmacy Company Profile (NYSE:DPLO)

About Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy logoDiplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

Industry, Sector and Symbol:
  • Sector: Retail/Wholesale
  • Industry: Food Retail & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:DPLO
  • CUSIP: N/A
  • Web: diplomat.is
Capitalization:
  • Market Cap: $1.11 billion
  • Outstanding Shares: 67,983,000
Average Prices:
  • 50 Day Moving Avg: $15.41
  • 200 Day Moving Avg: $15.82
  • 52 Week Range: $12.25 - $34.80
P/E:
  • Trailing P/E Ratio: 90.55
  • Foreward P/E Ratio: 20.85
  • P/E Growth: 1.50
Sales & Book Value:
  • Annual Revenue: $4.53 billion
  • Price / Sales: 0.24
  • Book Value: $9.35 per share
  • Price / Book: 1.74
Profitability:
  • EBIDTA: $70.47 million
  • Net Margins: 0.27%
  • Return on Equity: 7.97%
  • Return on Assets: 4.47%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 1.40%
  • Quick Ratio: 0.88%
Misc:
  • Average Volume: 638,983 shs.
  • Beta: 0.66
  • Short Ratio: 10.4
 
Frequently Asked Questions for Diplomat Pharmacy (NYSE:DPLO)

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy, Inc. (NYSE:DPLO) released its quarterly earnings results on Monday, August, 7th. The company reported $0.25 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.15 by $0.10. The business had revenue of $1.13 billion for the quarter, compared to analysts' expectations of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The company's revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.23 earnings per share. View Diplomat Pharmacy's Earnings History.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy issued an update on its FY17 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $0.71-0.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.65. The company issued revenue guidance of $4.3-4.6 billion, compared to the consensus revenue estimate of $4.57 billion.

Where is Diplomat Pharmacy's stock going? Where will Diplomat Pharmacy's stock price be in 2017?

11 equities research analysts have issued twelve-month price targets for Diplomat Pharmacy's stock. Their predictions range from $13.00 to $20.00. On average, they anticipate Diplomat Pharmacy's share price to reach $17.89 in the next year. View Analyst Ratings for Diplomat Pharmacy.

What are analysts saying about Diplomat Pharmacy stock?

Here are some recent quotes from research analysts about Diplomat Pharmacy stock:

  • 1. According to Zacks Investment Research, "Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. " (8/9/2017)
  • 2. Mizuho analysts commented, "We are reiterating our price target of $17 while lowering our 2017E and 2018E adjusted EPS to $0.62 and $0.75, respectively. We think initial 2017 guidance removed an overhang. Further, assumptions embedded in guidance, including drug price inflation and DIR payments, appear conservative which reduces the risk of further guidance reductions throughout the year in our view." (3/1/2017)

Who are some of Diplomat Pharmacy's key competitors?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:

  • Joel Saban, President
  • Atul Kavthekar, Chief Financial Officer
  • Gary Rice, Executive Vice President - Operations
  • Philip R. Hagerman, Chairman of the Board, Chief Executive Officer, Co-Founder
  • Benjamin Wolin, Lead Independent Director
  • Regina M. Benjamin M.D., Independent Director
  • David C. Dreyer CPA, Independent Director
  • Kenneth O. Klepper, Independent Director
  • Shawn Cline Tomasello, Independent Director

Who owns Diplomat Pharmacy stock?

Diplomat Pharmacy's stock is owned by many different of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (8.45%), Janus Henderson Group PLC (6.71%), Vanguard Group Inc. (6.07%), Davis Selected Advisers (2.54%), Hermes Investment Management Ltd. (2.42%) and Riverbridge Partners LLC (2.10%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Gary W Kadlec, Philip R Hagerman and Sean Whelan. View Institutional Ownership Trends for Diplomat Pharmacy.

Who sold Diplomat Pharmacy stock? Who is selling Diplomat Pharmacy stock?

Diplomat Pharmacy's stock was sold by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Thrivent Financial For Lutherans, Hermes Investment Management Ltd., Riverbridge Partners LLC, GW&K Investment Management LLC, Cambridge Investment Research Advisors Inc., Capital Impact Advisors LLC and Employees Retirement System of Texas. View Insider Buying and Selling for Diplomat Pharmacy.

Who bought Diplomat Pharmacy stock? Who is buying Diplomat Pharmacy stock?

Diplomat Pharmacy's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Northern Trust Corp, Fred Alger Management Inc., Tekla Capital Management LLC, Koch Industries Inc., JPMorgan Chase & Co., Frontier Capital Management Co. LLC and Cornerstone Capital Management Holdings LLC.. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy Diplomat Pharmacy stock?

Shares of Diplomat Pharmacy can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of Diplomat Pharmacy stock can currently be purchased for approximately $16.26.


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Diplomat Pharmacy (NYSE:DPLO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.09)
Consensus Price Target: $17.89 (10.04% upside)

Analysts' Ratings History for Diplomat Pharmacy (NYSE:DPLO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Needham & Company LLCInitiated CoverageBuy -> Buy$19.75LowView Rating Details
5/25/2017Bank of America CorporationBoost Price TargetNeutral$17.00 -> $18.50LowView Rating Details
5/17/2017Leerink SwannReiterated RatingMarket Perform$16.00 -> $18.00LowView Rating Details
5/16/2017MizuhoBoost Price TargetNeutral -> Neutral$17.00 -> $19.00LowView Rating Details
5/9/2017Barclays PLCSet Price TargetBuy$17.00 -> $20.00LowView Rating Details
5/9/2017Cowen and CompanyBoost Price TargetMarket Perform$12.00 -> $17.00MediumView Rating Details
11/23/2016Credit Suisse GroupDowngradeNeutral -> Underperform$18.00 -> $13.00N/AView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
11/3/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformN/AView Rating Details
11/3/2016Citigroup Inc.DowngradeMarket PerformN/AView Rating Details
11/3/2016Avondale PartnersDowngradeOutperform -> Market PerformN/AView Rating Details
5/19/2016William BlairReiterated RatingOutperformN/AView Rating Details
5/10/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
10/2/2015Morgan StanleyDowngradeOverweight -> Equal Weight$58.00 -> $31.00N/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for Diplomat Pharmacy (NYSE:DPLO)
Earnings by Quarter for Diplomat Pharmacy (NYSE:DPLO)
Earnings History by Quarter for Diplomat Pharmacy (NYSE DPLO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017$0.15$0.25$1.14 billion$1.13 billionViewListenView Earnings Details
5/8/2017Q1 2017$0.15$0.19$1.08 billion$1.08 billionViewListenView Earnings Details
2/28/2017Q416$0.16$0.08$1.18 billion$1.14 billionViewListenView Earnings Details
11/2/2016Q316$0.24$0.21$1.26 billion$1.18 billionViewN/AView Earnings Details
8/9/2016Q216$0.21$0.23$1.12 billion$1.09 billionViewN/AView Earnings Details
5/9/2016Q116$0.18$0.23$984.28 million$995.90 millionViewN/AView Earnings Details
2/29/2016Q415$0.20$0.21$969.70 million$987.00 millionViewListenView Earnings Details
11/3/2015Q315$0.16$0.26$928.86 million$946.90 millionViewN/AView Earnings Details
8/3/2015Q215$0.12$0.16$738.99 million$808.01 millionViewN/AView Earnings Details
5/11/2015Q115$0.08$0.09$629.60 million$625.00 millionViewListenView Earnings Details
3/2/2015Q414$0.06$0.08$603.70 million$603.67 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Diplomat Pharmacy (NYSE:DPLO)
Current Year EPS Consensus Estimate: $0.75 EPS
Next Year EPS Consensus Estimate: $0.78 EPS

Dividends

Dividend History for Diplomat Pharmacy (NYSE:DPLO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Diplomat Pharmacy (NYSE:DPLO)
Insider Ownership Percentage: 35.40%
Institutional Ownership Percentage: 71.64%
Insider Trades by Quarter for Diplomat Pharmacy (NYSE:DPLO)
Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)
Insider Trades by Quarter for Diplomat Pharmacy (NYSE:DPLO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Atheer A KaddisEVPSell20,000$30.12$602,400.00View SEC Filing  
8/1/2016Atheer A KaddisEVPSell12,325$35.76$440,742.00View SEC Filing  
7/1/2016Atheer A KaddisEVPSell12,325$35.04$431,868.00View SEC Filing  
6/1/2016Atheer A KaddisEVPSell12,325$32.31$398,220.75View SEC Filing  
5/2/2016Atheer A KaddisEVPSell12,325$30.17$371,845.25View SEC Filing  
4/15/2016Atheer A KaddisEVPSell24,650$30.00$739,500.00View SEC Filing  
2/12/2016Atheer A. KaddisEVPSell12,325$30.00$369,750.00View SEC Filing  
12/7/2015Philip R HagermanCEOSell2,300,000$33.60$77,280,000.00View SEC Filing  
12/1/2015Atheer A. KaddisSVPSell12,325$34.75$428,293.75View SEC Filing  
12/1/2015Gary W. KadlecPresidentSell30,000$34.93$1,047,900.00View SEC Filing  
11/3/2015Atheer A. KaddisSVPSell24,650$30.00$739,500.00View SEC Filing  
11/2/2015Gary W. KadlecPresidentSell30,000$28.03$840,900.00View SEC Filing  
10/1/2015Gary W. KadlecPresidentSell30,000$27.66$829,800.00View SEC Filing  
9/8/2015Atheer A. KaddisSVPSell12,325$37.42$461,201.50View SEC Filing  
9/1/2015Gary W. KadlecPresidentSell30,000$38.05$1,141,500.00View SEC Filing  
8/26/2015Sean WhelanCFOSell149,534$38.04$5,688,273.36View SEC Filing  
3/25/2015David C DreyerDirectorBuy1,034$29.00$29,986.00View SEC Filing  
3/25/2015Jeffrey M RoweEVPSell600,000$29.00$17,400,000.00View SEC Filing  
3/25/2015Philip R HagermanCEOSell1,801,000$29.00$52,229,000.00View SEC Filing  
10/9/2014Atheer A KaddisSVPBuy4,000$13.00$52,000.00View SEC Filing  
10/9/2014Jeffrey M RoweEVPSell416,666$13.00$5,416,658.00View SEC Filing  
10/9/2014Philip R HagermanCEOSell2,916,666$13.00$37,916,658.00View SEC Filing  
10/9/2014Sean WhelanCFOBuy2,000$13.00$26,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Diplomat Pharmacy (NYSE:DPLO)
Latest Headlines for Diplomat Pharmacy (NYSE:DPLO)
Source:
DateHeadline
nasdaq.com logo5 Stocks Worth a Look After Broker Rating Upgrades - Nasdaq
www.nasdaq.com - August 16 at 6:21 PM
prnewswire.com logoDiplomat Dispensing Opioid-Overdose Antidote Naloxone - PR Newswire (press release)
www.prnewswire.com - August 15 at 6:44 PM
finance.yahoo.com logoDiplomat Dispensing Opioid-Overdose Antidote Naloxone
finance.yahoo.com - August 15 at 6:43 PM
finance.yahoo.com logoEnvoyHealth Partners With Health Care Management Company PharMedQuest
finance.yahoo.com - August 14 at 6:22 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (DPLO) Upgraded to C- by TheStreet
www.americanbankingnews.com - August 12 at 4:32 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (NYSE:DPLO) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - August 9 at 7:16 PM
finance.yahoo.com logoDiplomat Pharmacy, Inc. breached its 50 day moving average in a Bullish Manner : DPLO-US : August 9, 2017
finance.yahoo.com - August 9 at 6:09 PM
finance.yahoo.com logoEdited Transcript of DPLO earnings conference call or presentation 7-Aug-17 9:00pm GMT
finance.yahoo.com - August 8 at 10:45 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (NYSE:DPLO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 8 at 8:50 AM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (NYSE:DPLO) Releases Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - August 7 at 9:16 PM
finance.yahoo.com logoInvestor Network: Diplomat Pharmacy, Inc. to Host Earnings Call
finance.yahoo.com - August 7 at 6:17 PM
finance.yahoo.com logoDiplomat Announces A New President
finance.yahoo.com - August 7 at 6:17 PM
finance.yahoo.com logoDiplomat Announces 2nd Quarter Financial Results
finance.yahoo.com - August 7 at 6:17 PM
finance.yahoo.com logoDiplomat Pharmaceuticals posts 2Q profit
finance.yahoo.com - August 7 at 6:17 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (NYSE:DPLO) Updates FY17 Earnings Guidance
www.americanbankingnews.com - August 7 at 5:36 PM
americanbankingnews.com logoAnalyzing SuperValu (SVU) and Diplomat Pharmacy (NYSE:DPLO)
www.americanbankingnews.com - August 7 at 8:26 AM
americanbankingnews.com logoZacks: Brokerages Expect Diplomat Pharmacy, Inc. (DPLO) Will Post Quarterly Sales of $1.14 Billion
www.americanbankingnews.com - August 6 at 7:54 AM
prnewswire.com logoDIPLOMAT PHARMACY INVESTIGATION INITIATED BY FORMER ... - PR Newswire (press release)
www.prnewswire.com - August 5 at 5:16 PM
finance.yahoo.com logoDIPLOMAT PHARMACY INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Diplomat Pharmacy, Inc. - DPLO
finance.yahoo.com - August 4 at 11:12 PM
americanbankingnews.com logo Brokerages Expect Diplomat Pharmacy, Inc. (NYSE:DPLO) to Post $0.15 EPS
www.americanbankingnews.com - August 4 at 12:28 PM
prnewswire.com logoDiplomat Named Exclusive Distributor of NITYR™ - PR Newswire - PR Newswire (press release)
www.prnewswire.com - August 4 at 3:11 AM
businesswire.com logoCycle Pharmaceuticals Partners with Diplomat to Dispense Nityr - Business Wire (press release)
www.businesswire.com - August 3 at 10:10 PM
finance.yahoo.com logoDiplomat Named Exclusive Distributor of NITYR™
finance.yahoo.com - August 3 at 5:04 PM
prnewswire.com logoDiplomat Named Among Fastest-Growing Companies in Southeast Michigan - PR Newswire (press release)
www.prnewswire.com - August 1 at 11:39 PM
americanbankingnews.com logoSprouts Farmers Market (SFM) versus Diplomat Pharmacy (DPLO) Financial Review
www.americanbankingnews.com - August 1 at 10:24 AM
finance.yahoo.com logoDiplomat Named Among Fastest-Growing Companies in Southeast Michigan
finance.yahoo.com - July 31 at 5:49 PM
businesswire.com logoDIPLOMAT PHARMACY INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC ... - Business Wire (press release)
www.businesswire.com - July 29 at 12:59 AM
americanbankingnews.com logoGNC Holdings (GNC) & Diplomat Pharmacy (DPLO) Financial Survey
www.americanbankingnews.com - July 28 at 10:27 PM
prnewswire.com logoDiplomat Now Dispensing VOSEVI™ to Treat Chronic Hepatitis C Virus - PR Newswire (press release)
www.prnewswire.com - July 27 at 6:30 PM
finance.yahoo.com logoDiplomat Partners With Labor Value Rx to Support Specialty Members
finance.yahoo.com - July 27 at 6:30 PM
finance.yahoo.com logoDiplomat Now Dispensing VOSEVI™ to Treat Chronic Hepatitis C Virus
finance.yahoo.com - July 26 at 6:36 PM
prnewswire.com logoDiplomat to Release Second Quarter 2017 Operating Results and Host Conference ...
www.prnewswire.com - July 25 at 3:52 AM
finance.yahoo.com logoDiplomat to Release Second Quarter 2017 Operating Results and Host Conference Call on Monday, August 7, 2017
finance.yahoo.com - July 24 at 5:47 PM
finance.yahoo.com logoETFs with exposure to Diplomat Pharmacy, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:47 PM
finance.yahoo.com logoDIPLOMAT PHARMACY (DPLO) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating Diplomat Pharmacy, Inc. for Potential Securities Violations and Breaches of Fiduciary Duty
finance.yahoo.com - July 24 at 10:29 AM
americanbankingnews.com logoNeedham & Company LLC Begins Coverage on Diplomat Pharmacy, Inc. (NYSE:DPLO)
www.americanbankingnews.com - July 22 at 7:02 PM
finance.yahoo.com logoNERLYNX™ (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting
finance.yahoo.com - July 20 at 8:07 PM
finance.yahoo.com logoFool Mailbag: When Should You Double Down on a Falling Stock?
finance.yahoo.com - July 18 at 7:33 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (DPLO) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - July 17 at 6:42 PM
americanbankingnews.com logo Brokerages Anticipate Diplomat Pharmacy Inc (NYSE:DPLO) Will Post Quarterly Sales of $1.14 Billion
www.americanbankingnews.com - July 15 at 9:52 AM
finance.yahoo.com logoETFs with exposure to Diplomat Pharmacy, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:57 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (DPLO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 11:20 AM
americanbankingnews.com logo Analysts Expect Diplomat Pharmacy, Inc. (DPLO) Will Post Earnings of $0.15 Per Share
www.americanbankingnews.com - July 13 at 8:13 AM
finance.yahoo.com logoThriveRx Celebrates 10th Anniversary, Launches New Platforms
finance.yahoo.com - July 6 at 7:19 PM
americanbankingnews.com logoDiplomat Pharmacy, Inc. (DPLO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - June 29 at 9:14 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Walt Disney, Spectranetics, Koppers, FedEx, Rite Aid - Nasdaq
www.nasdaq.com - June 28 at 5:48 PM
finance.yahoo.com logoETFs with exposure to Diplomat Pharmacy, Inc. : June 28, 2017
finance.yahoo.com - June 28 at 5:48 PM
finance.yahoo.com logoDiplomat Pharmacy, Inc. – Value Analysis (NYSE:DPLO) : June 28, 2017
finance.yahoo.com - June 28 at 5:48 PM
nasdaq.com logoDiplomat Pharmacy Enters Oversold Territory (DPLO)
www.nasdaq.com - June 27 at 5:04 PM
finance.yahoo.com logoDiplomat Pharmacy, Inc. breached its 50 day moving average in a Bearish Manner : DPLO-US : June 27, 2017
finance.yahoo.com - June 27 at 5:04 PM

Social

Chart

Diplomat Pharmacy (DPLO) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff